Pennsaid
diclofenac sodium
Treatment for OsteoarthritisNuvo Receives Approvable Letter From U.S. FDA for Pennsaid
About Nuvo Research Inc.
Nuvo is focused on developing innovative site-specific therapeutics that are delivered topically using the Company's skin-penetrating technologies. Nuvo's lead product is Pennsaid(R), a topical non-steroidal anti-inflammatory (NSAID) used for the treatment of osteoarthritis. Nuvo intends to leverage its skin-penetrating technologies to create a portfolio of transdermal products targeting a variety of indications.Nuvo Research Inc. is a publicly traded, Canadian pharmaceutical company headquartered in Mississauga, Ontario, with its research and development facility in San Diego, California and manufacturing facilities in Varennes, Quebec and Wanzleben, Germany. For more information, please visit www.nuvoresearch.com.
Related Articles:
FDA Approves Pennsaid Topical Solution - November 5, 2009
FDA Extends Review of Pennsaid Diclofenac Sodium Topical Solution - August 5, 2009
FDA Accepts Nuvo's Resubmission For Pennsaid - February 19, 2009
Nuvo Provides Update on Discussions with the FDA Related to Pennsaid Approval - June 19, 2007
Nuvo Continues Discussions with the FDA Related to Pennsaid - June 6, 2007
Nuvo announces further update on discussions with the FDA related to review of Pennsaid - March 7, 2007
Nuvo Announces Update on Discussions With FDA Related to Approval of Pennsaid - February 9, 2007
Nuvo’s Pennsaid NDA Resubmission Accepted for Review by U.S. FDA - July 13, 2006
New Drug Applications Archive
2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
